Key statistics
As of last trade, Formycon AG (FYB:HAM) traded at 51.90, 35.69% above the 52 week low of 38.25 set on Apr 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 51.90 |
---|---|
High | 51.90 |
Low | 51.90 |
Bid | 52.30 |
Offer | 52.50 |
Previous close | 52.10 |
Average volume | 55.56 |
---|---|
Shares outstanding | 17.66m |
Free float | 7.43m |
P/E (TTM) | 13.08 |
Market cap | 923.46m EUR |
EPS (TTM) | 4.00 EUR |
Data delayed at least 15 minutes, as of Oct 09 2024 07:16 BST.
More ▼
Announcements
- Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
- EQS-News: Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
- EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
- EQS-News: Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases